Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The EMBO journal 2012-05, Vol.31 (11), p.2629-2647
Hauptverfasser: Röring, Michael, Herr, Ricarda, Fiala, Gina J, Heilmann, Katharina, Braun, Sandra, Eisenhardt, Anja E, Halbach, Sebastian, Capper, David, von Deimling, Andreas, Schamel, Wolfgang W, Saunders, Darren N, Brummer, Tilman
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2647
container_issue 11
container_start_page 2629
container_title The EMBO journal
container_volume 31
creator Röring, Michael
Herr, Ricarda
Fiala, Gina J
Heilmann, Katharina
Braun, Sandra
Eisenhardt, Anja E
Halbach, Sebastian
Capper, David
von Deimling, Andreas
Schamel, Wolfgang W
Saunders, Darren N
Brummer, Tilman
description The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf wt and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf V600E , B‐Raf insT and B‐Raf G469A oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf wt , B‐Raf V600E displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf wt and Raf‐1 wt mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation. An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.
doi_str_mv 10.1038/emboj.2012.100
format Article
fullrecord <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3365413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1018369830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</originalsourceid><addsrcrecordid>eNptkUFv1DAQhS0EokvhyhFF4sKhaWfsteNckOh2KVQtIATt0XISJ3ibOFs7ge6_r5eUVUGcPE_zvfHYj5CXCIcITB6ZruhXhxSQRg2PyAznAlIKGX9MZkAFpnOU-R55FsIKALjM8CnZo5QjSDmfkebEhsG6cki8uRmtN51xQ1L3PtEusW7QsVPZzvitML7WpYlV8su2VTps1uYguRQAy0hXybV1Opi0MrpKjtOvuk6CbZxuW-ua5-RJrdtgXtyf--T7--W3xYf0_PPpx8W787TkwCEtBfICqZaCM50hzanJUJd5zQRWwHIoa5oVUvIKa1pwEIxjzWKh87wqIWf75O00dz0WnanK-BqvW7X2ttN-o3pt1d8dZ3-opv-pGBN8jiwOeHM_wPc3owmD6mwoTdtqZ_oxKASUTOSSQURf_4Ou-tHHB0-UyDnlIlKvHm60W-VPBhHIJiB-qtns-ghqm7D6nbDaJhw1qOXF8dlWxDo6jyZniCbXGP9wgf-5oyOdHDF1c7u7S_trJTKWcXX16VQtFldfzoBeqEt2B0ert4g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018695256</pqid></control><display><type>article</type><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><source>Springer Nature OA Free Journals</source><creator>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</creator><creatorcontrib>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</creatorcontrib><description>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf wt and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf V600E , B‐Raf insT and B‐Raf G469A oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf wt , B‐Raf V600E displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf wt and Raf‐1 wt mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation. An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</description><identifier>ISSN: 0261-4189</identifier><identifier>EISSN: 1460-2075</identifier><identifier>DOI: 10.1038/emboj.2012.100</identifier><identifier>PMID: 22510884</identifier><identifier>CODEN: EMJODG</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>A-Raf ; Benzenesulfonates - pharmacology ; BRAF ; Caco-2 Cells ; Cancer ; EMBO24 ; EMBO37 ; Gene expression ; HCT116 Cells ; HT29 Cells ; Humans ; Indoles - pharmacology ; Kinases ; MAP Kinase Signaling System - drug effects ; MAP Kinase Signaling System - physiology ; Molecular biology ; Mutation ; Niacinamide - analogs &amp; derivatives ; Phenylurea Compounds ; PLX 4032/4720 ; Protein Kinase Inhibitors - pharmacology ; Protein Multimerization - drug effects ; Protein Multimerization - physiology ; Proto-Oncogene Proteins B-raf - metabolism ; Pyridines - pharmacology ; Signal transduction ; sorafenib ; Sulfonamides - pharmacology ; V600E-specific antibody</subject><ispartof>The EMBO journal, 2012-05, Vol.31 (11), p.2629-2647</ispartof><rights>European Molecular Biology Organization 2012</rights><rights>Copyright © 2012 European Molecular Biology Organization</rights><rights>Copyright Nature Publishing Group May 30, 2012</rights><rights>Copyright © 2012, European Molecular Biology Organization 2012 European Molecular Biology Organization</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365413/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365413/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27903,27904,41099,42168,45553,45554,46387,46811,51554,53769,53771</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.1038/emboj.2012.100$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22510884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Röring, Michael</creatorcontrib><creatorcontrib>Herr, Ricarda</creatorcontrib><creatorcontrib>Fiala, Gina J</creatorcontrib><creatorcontrib>Heilmann, Katharina</creatorcontrib><creatorcontrib>Braun, Sandra</creatorcontrib><creatorcontrib>Eisenhardt, Anja E</creatorcontrib><creatorcontrib>Halbach, Sebastian</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Schamel, Wolfgang W</creatorcontrib><creatorcontrib>Saunders, Darren N</creatorcontrib><creatorcontrib>Brummer, Tilman</creatorcontrib><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><title>The EMBO journal</title><addtitle>EMBO J</addtitle><addtitle>EMBO J</addtitle><description>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf wt and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf V600E , B‐Raf insT and B‐Raf G469A oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf wt , B‐Raf V600E displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf wt and Raf‐1 wt mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation. An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</description><subject>A-Raf</subject><subject>Benzenesulfonates - pharmacology</subject><subject>BRAF</subject><subject>Caco-2 Cells</subject><subject>Cancer</subject><subject>EMBO24</subject><subject>EMBO37</subject><subject>Gene expression</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Kinases</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>MAP Kinase Signaling System - physiology</subject><subject>Molecular biology</subject><subject>Mutation</subject><subject>Niacinamide - analogs &amp; derivatives</subject><subject>Phenylurea Compounds</subject><subject>PLX 4032/4720</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Multimerization - drug effects</subject><subject>Protein Multimerization - physiology</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>Pyridines - pharmacology</subject><subject>Signal transduction</subject><subject>sorafenib</subject><subject>Sulfonamides - pharmacology</subject><subject>V600E-specific antibody</subject><issn>0261-4189</issn><issn>1460-2075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkUFv1DAQhS0EokvhyhFF4sKhaWfsteNckOh2KVQtIATt0XISJ3ibOFs7ge6_r5eUVUGcPE_zvfHYj5CXCIcITB6ZruhXhxSQRg2PyAznAlIKGX9MZkAFpnOU-R55FsIKALjM8CnZo5QjSDmfkebEhsG6cki8uRmtN51xQ1L3PtEusW7QsVPZzvitML7WpYlV8su2VTps1uYguRQAy0hXybV1Opi0MrpKjtOvuk6CbZxuW-ua5-RJrdtgXtyf--T7--W3xYf0_PPpx8W787TkwCEtBfICqZaCM50hzanJUJd5zQRWwHIoa5oVUvIKa1pwEIxjzWKh87wqIWf75O00dz0WnanK-BqvW7X2ttN-o3pt1d8dZ3-opv-pGBN8jiwOeHM_wPc3owmD6mwoTdtqZ_oxKASUTOSSQURf_4Ou-tHHB0-UyDnlIlKvHm60W-VPBhHIJiB-qtns-ghqm7D6nbDaJhw1qOXF8dlWxDo6jyZniCbXGP9wgf-5oyOdHDF1c7u7S_trJTKWcXX16VQtFldfzoBeqEt2B0ert4g</recordid><startdate>20120530</startdate><enddate>20120530</enddate><creator>Röring, Michael</creator><creator>Herr, Ricarda</creator><creator>Fiala, Gina J</creator><creator>Heilmann, Katharina</creator><creator>Braun, Sandra</creator><creator>Eisenhardt, Anja E</creator><creator>Halbach, Sebastian</creator><creator>Capper, David</creator><creator>von Deimling, Andreas</creator><creator>Schamel, Wolfgang W</creator><creator>Saunders, Darren N</creator><creator>Brummer, Tilman</creator><general>John Wiley &amp; Sons, Ltd</general><general>Nature Publishing Group UK</general><general>Blackwell Publishing Ltd</general><general>Nature Publishing Group</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PCBAR</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120530</creationdate><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><author>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>A-Raf</topic><topic>Benzenesulfonates - pharmacology</topic><topic>BRAF</topic><topic>Caco-2 Cells</topic><topic>Cancer</topic><topic>EMBO24</topic><topic>EMBO37</topic><topic>Gene expression</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Kinases</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>MAP Kinase Signaling System - physiology</topic><topic>Molecular biology</topic><topic>Mutation</topic><topic>Niacinamide - analogs &amp; derivatives</topic><topic>Phenylurea Compounds</topic><topic>PLX 4032/4720</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Multimerization - drug effects</topic><topic>Protein Multimerization - physiology</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>Pyridines - pharmacology</topic><topic>Signal transduction</topic><topic>sorafenib</topic><topic>Sulfonamides - pharmacology</topic><topic>V600E-specific antibody</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Röring, Michael</creatorcontrib><creatorcontrib>Herr, Ricarda</creatorcontrib><creatorcontrib>Fiala, Gina J</creatorcontrib><creatorcontrib>Heilmann, Katharina</creatorcontrib><creatorcontrib>Braun, Sandra</creatorcontrib><creatorcontrib>Eisenhardt, Anja E</creatorcontrib><creatorcontrib>Halbach, Sebastian</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Schamel, Wolfgang W</creatorcontrib><creatorcontrib>Saunders, Darren N</creatorcontrib><creatorcontrib>Brummer, Tilman</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Earth, Atmospheric &amp; Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Earth, Atmospheric &amp; Aquatic Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The EMBO journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Röring, Michael</au><au>Herr, Ricarda</au><au>Fiala, Gina J</au><au>Heilmann, Katharina</au><au>Braun, Sandra</au><au>Eisenhardt, Anja E</au><au>Halbach, Sebastian</au><au>Capper, David</au><au>von Deimling, Andreas</au><au>Schamel, Wolfgang W</au><au>Saunders, Darren N</au><au>Brummer, Tilman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</atitle><jtitle>The EMBO journal</jtitle><stitle>EMBO J</stitle><addtitle>EMBO J</addtitle><date>2012-05-30</date><risdate>2012</risdate><volume>31</volume><issue>11</issue><spage>2629</spage><epage>2647</epage><pages>2629-2647</pages><issn>0261-4189</issn><eissn>1460-2075</eissn><coden>EMJODG</coden><abstract>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf wt and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf V600E , B‐Raf insT and B‐Raf G469A oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf wt , B‐Raf V600E displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf wt and Raf‐1 wt mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation. An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>22510884</pmid><doi>10.1038/emboj.2012.100</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0261-4189
ispartof The EMBO journal, 2012-05, Vol.31 (11), p.2629-2647
issn 0261-4189
1460-2075
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3365413
source Springer Nature OA Free Journals
subjects A-Raf
Benzenesulfonates - pharmacology
BRAF
Caco-2 Cells
Cancer
EMBO24
EMBO37
Gene expression
HCT116 Cells
HT29 Cells
Humans
Indoles - pharmacology
Kinases
MAP Kinase Signaling System - drug effects
MAP Kinase Signaling System - physiology
Molecular biology
Mutation
Niacinamide - analogs & derivatives
Phenylurea Compounds
PLX 4032/4720
Protein Kinase Inhibitors - pharmacology
Protein Multimerization - drug effects
Protein Multimerization - physiology
Proto-Oncogene Proteins B-raf - metabolism
Pyridines - pharmacology
Signal transduction
sorafenib
Sulfonamides - pharmacology
V600E-specific antibody
title Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T05%3A21%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20requirement%20for%20an%20intact%20dimer%20interface%20in%20wild-type,%20V600E%20and%20kinase-dead%20B-Raf%20signalling&rft.jtitle=The%20EMBO%20journal&rft.au=R%C3%B6ring,%20Michael&rft.date=2012-05-30&rft.volume=31&rft.issue=11&rft.spage=2629&rft.epage=2647&rft.pages=2629-2647&rft.issn=0261-4189&rft.eissn=1460-2075&rft.coden=EMJODG&rft_id=info:doi/10.1038/emboj.2012.100&rft_dat=%3Cproquest_C6C%3E1018369830%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018695256&rft_id=info:pmid/22510884&rfr_iscdi=true